Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated patients achieve disease stabilisation or better at the first radiological evaluation. In addition to that a particularly broad spectrum of toxicities (experienced as G3 or more NCI CTCAE gr...

OBJECTIVE To investigate annexin-based optical fluorescence imaging (OI) for monitoring regorafenib-induced early cell death in experimental colon carcinomas in rats, validated by perfusion MRI and multiparametric immunohistochemistry. MATERIALS AND METHODS Subcutaneous human colon carcinomas (HT-29) in athymic rats (n = 16) were imaged before and after a one-week therapy with regorafenib (n ...

Regorafenib is a multikinase inhibitor which showed benefits in pretreated metastatic colorectal cancer patients. Hepatotoxicity has been described as a frequent side effect. We report the case of a 65-year-old patient presenting with jaundice, fever, and hepatocellular insufficiency which led to death of the patient. She had previously been treated with several lines of chemotherapy for sub- a...

101 Background: The genotype of primary mutations predicts imatinib response in untreated metastatic GIST. However, the sequence salvage treatments GIST is based solely on chronological order registration trials. ctDNA sequencing offers a powerful diagnostic tool to detect resistance but has not been shown correlate with outcomes clinical trials pretreated patients (pts). We analyzed samples co...

Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38%, and there were assoc...

We investigated the patients with solid cancers harboring Fms-like tyrosine kinase 3 (FLT3) amplification using targeted sequencing of tumor tissue specimen and FISH assay. Simultaneously, FLT3-amplified patient-derived cells (PDCs) were generated to evaluate the sensitivity to FLT3 inhibition. A patient with metastatic colon cancer who was previously treated with more than 3rd line cytotoxic c...

BACKGROUND Colorectal cancer (CRC) that has metastasized before being discovered, or reoccurs following surgery, remains a major treatment challenge. Trials have established the usefulness of antiangiogenic agents and new regimens in prolonging survival in patients with advanced disease. In the United States, the antiangiogenic agents approved for treating metastatic CRC often are combined with...

Affiliations of authors: Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy (VF, GN); Department of Surgical, Oncology and Oral Sciences, Sector of Oral Medicine, Palermo University, Palermo, Italy (GC); University of Tennessee Health Science Center, College of Dentistry, Memphis, TN (CM); DH Oncology, Universit a Campus Bio-Medico, Rome, Italy (DS); Department of N...

Regorafenib is an oral multikinase inhibitor approved for advanced mCRC, gastrointestinal stromal tumors, and hepatocellular carcinoma. The phase 2 regorafenib dose-optimization study (ReDOS; Bekaii-Saab TS, et al., 2019) demonstrated that patients could initiate at a dose of 80 mg/day then subsequently escalate their depending on tolerability without compromising efficacy. In March 2018, the R...